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Abstract
Brain fatty acid–binding protein (B-FABP) is normally
expressed in radial glial cells, where it plays a role
in the establishment of the radial glial fiber network
required for neuronal migration. B-FABP is also ex-
pressed in astrocytoma tumors and in some malignant
glioma cell lines. To address the role of B-FABP in
malignant glioma, we have studied the growth proper-
ties of clonal populations of malignant glioma cells
modified for B-FABP expression. Here, we demonstrate
that expression of B-FABP in B-FABP–negative malig-
nant glioma cells is accompanied by the appearance
of radial glial–like properties, such as increased migra-
tion and extended bipolar cell processes, as well as
reduced transformation. Conversely, B-FABP depletion
in B-FABP–positive malignant glioma cells results in
decreased migration, reduction in cell processes, and
a more transformed phenotype. Moreover, expression
of B-FABP in astrocytomas is associated with regions
of tumor infiltration and recurrence. Rather than being
a direct manifestation of the tumorigenic process, we
propose that the ability of high-grade astrocytoma cells
to migrate long distances from the primary tumor re-
flects properties associated with their cell of origin.
Thus, targeting B-FABP–expressing cells may make a
significant impact on the treatment of these tumors.
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Introduction
Astrocytomas, classified as grades I to IV by the World
Health Organization, are the most common central nervous
system malignancies in humans. Grade III and grade IV
astrocytomas, collectively referred to as high-grade malig-
nant gliomas, are very aggressive, with patients diagnosed
with these tumors having median survivals of 1.6 years and
5 months, respectively [1]. Although they have a higher
survival rate, grade II astrocytomas frequently recur as
high-grade astrocytomas, making the treatment of these
tumors particularly challenging.
In spite of aggressive treatment often involving a com-
bination of surgical resection, radiation therapy, and che-
motherapy, patients with high-grade astrocytomas usually
present with secondary brain tumors at sites that can be distal
from the primary tumor mass. Yet extracranial spread of the
disease is rare for high-grade astrocytomas, occurring in only
0.4% to 2.3% of patients [2,3]. The aggressive nature of high-
grade astrocytomas may, therefore, reflect inherently migratory/
infiltrative properties of the tumor cell of origin rather than ac-
quired invasive properties. Astrocytomas are traditionally be-
lieved to arise from astrocytes because they express glial
fibrillary acidic protein (GFAP), an astrocyte-specific marker.
More recently, it has been suggested that these tumors may
arise from pre-astrocytic transitional cells or multipotent neural
stem cells [4].
We have previously reported that a subset of malignant
glioma cell lines established from high-grade astrocytomas ex-
presses brain fatty acid–binding protein (B-FABP; aka FABP7
or BLBP) [5]. During brain development, B-FABP is expressed
in radial glial cells, where it plays a role in the establishment
and maintenance of the radial glial fiber system that guides
immature migrating neurons to their final destination [6,7]. The
addition of anti–B-FABP antibodies to primary cultures of
cerebellar cells blocks glial cell differentiation by preventing
the extension of radial glial processes [6]. Radial glial cells give
rise to GFAP-expressing astrocytes once neuronal migration
is completed [8]. Radial glial cells also display properties of
precursor cells, generating both neurons and glial cells in vitro,
and have been proposed to function as neural progenitor or
neural stem cells [9].
The FABP family consists of structurally related proteins
that have cell-, tissue-, and development-specific patterns of
expression. Roles for these proteins include the uptake and
intracellular trafficking of fatty acids, bile acids, and retinoids,
as well as roles in cell signaling, gene transcription, cell growth,
and differentiation [10]. Fatty acids serve as precursors for
signaling molecules, metabolic substrates, and membrane
Abbreviations: B-FABP, brain fatty acid – binding protein; GFAP, glial fibrillary acidic protein;
DHA, docosahexanoic acid; PPAR, peroxisome proliferator – activated receptor
Address all correspondence to: Roseline Godbout, Cross Cancer Institute, 11560 University
Avenue, Edmonton, Alberta, Canada T6G 1Z2. E-mail: rgodbout@ualberta.ca
1This article refers to supplementary material, which is designated by ‘‘W’’ (i.e., Figure W1)
and is available online at www.bcdecker.com.
2This work was supported by the National Cancer Institute of Canada with funds from the
Canadian Cancer Society and by a Research Initiative Program grant from the Alberta
Cancer Board.
3This paper is dedicated to the memory of Dr. John Rowe.
Received 26 May 2007; Revised 4 July 2007; Accepted 6 July 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.07439
Neoplasia . Vol. 9, No. 9, September 2007, pp 734–744 734
www.neoplasia.com
RESEARCH ARTICLE
phospholipid constituents, and are mediators of gene ex-
pression [10]. Reports suggest a link between FABP levels
and either increasing or decreasing malignancy. For ex-
ample, liver and intestinal FABP levels decrease with the
progression of liver and colon cancers, respectively [11,12].
Adipocyte FABP levels are higher in low-grade bladder
carcinoma than in high-grade tumors [13], whereas epider-
mal FABP is expressed at higher levels in prostate cancer
compared to prostatic hyperplasia [14]. Directly relevant
to our study, a recent gene profiling analysis of grade IV
astrocytoma revealed an inverse correlation between the
expression of nuclear B-FABP and survival in patients youn-
ger than the median age [15].
Here, we address the role of B-FABP in the growth and
migration properties of malignant glioma cells. We report
that stable introduction of a B-FABP expression construct
into a B-FABP–negative malignant glioma cell line reduces
its anchorage independence and enhances its migratory
properties. Conversely, reduction of B-FABP in B-FABP–
positive cells reduces its migratory properties. Analysis of
B-FABP distribution in astrocytoma tumors indicates ele-
vated levels of B-FABP in infiltrating regions of the tumors.
Our results suggest an important role for B-FABP in control-
ling the migration of malignant glioma cells. Based on our
in vitro and in vivo studies, we propose that B-FABP expres-
sion in astrocytoma tumors drives the infiltration of malig-
nant cells into adjacent brain tissues.
Materials and Methods
Stable Transfections
Cells were transfected by calcium phosphate–mediated
DNA transfection. The B-FABP expression construct was
prepared by inserting a 467-bp human B-FABP cDNA frag-
ment containing the entire open reading frame into the
pREP4 vector, which carries the gene for hygromycin resis-
tance. The pSUPER RNAi system (Oligoengine, Seattle,
WA) was used to reduce levels of B-FABP in U251 cells. A
64-bp inverted repeat-containing sense/antisense 19-nt
gene-specific sequence (CCAACGGTAATTATCAGTC; cor-
responding to B-FABP nt 114–132) was introduced into the
pSUPER vector at the Bgl II/HindIII site. For stable trans-
fectants, pSUPER vectors were cotransfected with a pREP4
empty vector. U87- and U251-transfected cells were selected
in 400 mg/ml hygromycin, and individual colonies were picked
using cloning rings.
Western Blot Analysis
Whole-cell lysates were electrophoresed in 13.5% SDS
polyacrylamide gels, followed by electroblotting onto nitrocel-
lulose. Blots were immunostained with rabbit anti–B-FABP
antibody prepared by immunizing rabbits with recombinant
glutathione S-transferase (GST)–tagged human B-FABP
(1:1000 dilution) [5] or goat anti-actin antibody (1:5000 dilu-
tion; SantaCruzBiotechnology, SantaCruz,CA). Primary anti-
bodies were detectedwith horseradish peroxidase–conjugated
secondary antibodies (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) using the ECL detection system (GE
Healthcare, Baie d’Urfe, Canada).
Cell Motility, Migration, and Invasion
Nondirectional cell motility was measured by 2D time-
lapse video microscopy. Cells were plated in triplicate
(75,000 cells/35-mm tissue culture dish) and cultured for
24 hours. Metamorph imaging software was used to capture
a single differential interference contrast (DIC) image every
30 seconds for 2 hours (241 images in total), with each im-
age containing 30 to 40 cells. A video was then constructed,
and the migration of single cells was tracked using the
Metamorph tracking function. Directional cell migration was
measured by plating 25,000 cells in DMEM in the upper
chamber of Transwell culture dishes (BD Falcon Labware,
Bedford, MA). Cells were allowed to migrate through an
8-mm polyethylene terephthalate (PET) membrane toward a
chemoattractant (DMEM + 10% fetal calf serum in a bottom
chamber) for 6 hours. Cells were then fixed in 70% methanol
and stained with 1% crystal violet. Cells were photographed
and counted using Metamorph cell-counting software. Cell
invasion was measured using BD Biocoat Matrigel invasion
chambers (BD Biosciences, San Jose, CA) following the
manufacturer’s directions. Top chambers were plated with
either 10,000 cells (for U87 transfectants) or 25,000 cells (for
U251 transfectants) in DMEM and incubated for 22 hours.
Cells were fixed, stained, and counted as described for the
Transwell migration assay.
Immunofluorescence and Immunohistochemical Analysis
For immunofluorescence analysis, cells growing on cov-
erslips were fixed in 1% paraformaldehyde in phosphate-
buffered saline for 10 minutes and permeabilized in 0.5%
Triton X-100 for 5 minutes. The cells were colabeled with
affinity-purified rabbit anti–B-FABP (1:200 dilution) followed
by Alexa-488 goat anti-rabbit (1:200 dilution) (Cedarlane
Laboratories, Burlington, Canada) and with Alexa-546 phal-
loidin (1:200 dilution) (Molecular Probes; Invitrogen, Carlsbad,
CA). Affinity purification of rabbit anti–B-FABP antibody [5] was
performed using Hi-Trap NHS-activated Sepharose columns
(GE Healthcare) linked to GST 4B–purified GST-B-FABP.
Images were collected on a Zeiss (Oberkochen, Germany)
LSM510 confocalmicroscopewith a 40/1.3 oil immersion lens.
For immunohistochemical analysis, grade II and grade IV
astrocytomas embedded in paraffin were obtained from
the Department of Pathology and Laboratory Medicine, Uni-
versity of Alberta (Edmonton, Alberta, Canada), or from the
Brain Tumor Tissue Bank, London Health Sciences Center,
London (Canada). Tissues were deparaffinized in xylene,
rehydrated, microwaved for 20 minutes in citrate/Tween-20
epitope retrieval buffer (pH 6), and incubated in affinity-purified
anti–B-FABP antibody (1:800 dilution) overnight at 4jC. Slides
were washed and incubated for 1 hour in DakoCytomation
EnvisionPlus anti-rabbit secondary antibody (DakoCytoma-
tion, Glostrup, Denmark). Immunoreactivity was detected
using DakoCytomation Liquid DAB+ Substrate Chromagen
System (DakoCytomation). The slides were counterstained
with hematoxylin. A low-magnification picture of the entire
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tissue section shown in Figure 6 was generated by taking 28
low-magnification pictures of the tissue and merging them
using Adobe Photoshop (Adobe Systems Incorporated, San
Jose, CA).
Results
Stable B-FABP Transfection of U87 Cells
To address the role of B-FABP in malignant glioma cells,
we stably transfected the B-FABP–negative U87 malignant
glioma cell line with a pREP4/B-FABP expression construct.
U87 cells transfected with an empty vector served as the con-
trol for these experiments. Control and B-FABP–transfected
cells were selected in hygromycin, and individual colonies
were picked using cloning rings.
B-FABP levels in four stable B-FABP transfectants (U87-
B1, U87-B2, U87-B3, and U87-B4) were examined by West-
ern blot analysis. As shown in Figure 1A, all four B-FABP
transfectants expressed B-FABP, with the highest levels ob-
served in U87-B4. B-FABP levels in U87-B4 were similar to
endogenous B-FABP levels found in B-FABP–expressing
U251 cells, with approximately three-fold lower levels ob-
served in U87-B1, U87-B2, and U87-B3. As expected,
B-FABP was not detected in the three pREP4 control trans-
fectants U87-(pREP4)R1, U87-R2, and U87-R3.
Depletion of B-FABP in U251 Cells
U251 cells express endogenous B-FABP. We used RNA
interference to reduce B-FABP levels in these cells. The
pSUPER vector was used for these experiments because it
allows long-term reduction in protein levels as a result of the
persistent production of short hairpin RNA in stable trans-
fectants. Nucleotides 114 to 132 of the B-FABP coding region
served as our target sequence, with pSUPER empty vec-
tor serving as the control. To select stable transfectants,
pSUPER constructs were cotransfected with pREP4 and
cells were selected in hygromycin. These colonies were
expanded and analyzed for B-FABP expression after at least
10 passages of a subconfluent culture in a 100-mm plate.
A 70% to 90% reduction in B-FABP levels was observed in
three U251 pSUPER/B-FABP transfectants, labeled U251-
B1, U251-B2, and U251-B3 (Figure 1B). All three control
transfectants [S(pSUPER)1, S2, and S3] showed sig-
nificantly higher levels of B-FABP compared to pSUPER/
B-FABP transfectants.
Morphologic Changes in U87 and U251 Transfectants
We used phase-contrast microscopy to study the mor-
phology of B-FABP–negative U87, control transfectants,
and B-FABP–expressing transfectants. The U87 parent cell
line and control transfectants generally had a stellate ap-
pearance with short processes (Figure 2A, top panels). In
contrast, B-FABP–expressing U87 cells formed extended
bipolar processes (indicated by arrowheads) often spanning
considerable distances (as much as 250 mm) (Figure 2A,
bottom panels). These elongated processes are similar in
appearance to radial glial processes that can span the entire
width of the cortical wall during brain development [16].
U251 cells generally form longer processes compared to
U87 cells, with the processes often having a bipolar appear-
ance. The morphology of all three U251 control transfectants
was similar to that of the parent U251 cells (Figure 2B, top
panels). Depletion of B-FABP in U251-B1, U251-B2, and
U251-B3 resulted in loss of elongated processes and the for-
mation of fan-like structures (indicated by arrowheads) usually
associated with extensive membrane ruffling (Figure 2B, bot-
tom panels). These fan-like structures were mainly observed
when the cells were subconfluent. No difference in cell piling
was observed for any of the transfectants at confluence.
B-FABP Expression and Cell Migration
B-FABP expression in malignant glioma cells results in
the formation of elongated processes that may be associated
with cell migration. We used two different approaches to
study the effect of B-FABP on malignant glioma cell motility:
1) 2D time-lapse video microscopy, which measures random
(or nondirected) movement; and 2) Transwell chambers,
which are used to measure directed migration toward a
chemoattractant (10% fetal calf serum).
Using 2D time-lapse video microscopy, we followed the
total movement off 100 cells per U87 clone over a period of
2 hours (30–40 cells were analyzed per experiment). All four
U87 B-FABP transfectants had a higher motility rate than con-
trol transfectants, with B-FABP–expressing U87 clones trav-
eling at 75 to 94 mm/hr compared to 48 to 58 mm/hr for controls
(Figure 3A). Differences in motility were found to be statisti-
cally significant using unpaired t-test (P < .001). Similar re-
sults were obtained with Transwell chambers, with B-FABP–
expressing transfectants being highly migratory compared
to control transfectants. A range of 1997 to 2997 cells mi-
grated through the porous filter toward the chemoattractant in
the case of U87 B-FABP transfectants, in contrast to 273 to
Figure 1. Western blot analysis of B-FABP in U87- and U251-transfected
cells. (A) Whole-cell extracts (50 g/lane) were prepared from U87 cells
stably transfected with empty pREP4 vector (R1, R2, and R3), U87 cells
stably transfected with pREP4/B-FABP (B1, B2, B3, and B4), and U251. (B)
Whole-cell extracts (50 g/lane) were prepared from U251 stably transfected
with empty pSUPER vector (S1, S2, and S3) and pSUPER/B-FABP (B1, B2,
and B3). Extracts were electrophoresed on a 13.5% SDS polyacrylamide gel.
Proteins were transferred to nitrocellulose membranes and sequentially
immunostained with rabbit anti –B-FABP antibody and goat anti-actin anti-
body, followed by horseradish peroxidase–conjugated secondary antibodies.
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816 cells in the case of U87 control transfectants (Figure 3C).
U87 B-FABP4, with the highest levels of B-FABP, had the
highest number of migrating cells. These differences in mi-
gration were highly significant (P < .0001).
Similar analyses carried out with B-FABP–depleted and
control U251 transfectants support a role for B-FABP in cell
motility. 2D time-lapse video microscopy revealed higher mo-
tility rates for U251 control transfectants, ranging from 60
to 63 mm/hr, compared to B-FABP–depleted U251 clones,
which ranged from 43 to 52 mm/hr (P < .001) (Figure 3B).
Results from Transwell chambers showed decreased mi-
gration as a function of B-FABP depletion, with 1726 to
1890 cells/well for U251 control transfectants compared to
617 to 950 cells/well for B-FABP–depleted U251 transfec-
tants (P < .0001) (Figure 3D).
B-FABP Expression and Invasion
We used the in vitro Matrigel invasion assay to deter-
mine whether the increased migration rate associated with
B-FABP expression in malignant glioma cells corresponded
to an increase in invasive properties. The Matrigel matrix is
a reconstituted basement membrane that is coated over a
filter with 8 mm pore size. The basement membrane pre-
vents noninvasive cells from migrating through the filter. This
assay has been widely used to study the invasive properties
of malignant glioma cells and has been shown to correlate
well with the 3D spheroid invasion assay and the in vivo
intracranial implantation assay [17].
U87- or U251-transfected cells were plated in the upper
compartments of Matrigel chambers and incubated at 37jC
for 22 hours. Cells that were able to pass through the
Matrigel matrix during this time period were stained and
counted. There was a trend toward increased cell invasion
as a result of B-FABP expression in U87 (P < .026), with 77
to 136 cells/well in the control group compared to 114 to
236 cells/well in the B-FABP–expressing group (Figure 3E ).
An approximately two-fold reduction in the number of invading
cells was observed in B-FABP–depleted U251 cells compared
to controls (P < .0001) (Figure 3F ).
B-FABP Expression, Cell Proliferation,
and Anchorage Independence
The doubling times of B-FABP–transfected U87 and
B-FABP–depleted U251 were measured at 24-hour intervals
when cells were in the exponential growth phase. B-FABP
expression in U87 cells resulted in a significant decrease
in proliferation rate. Doubling times ranged from 28 to
32.5 hours in control transfectants and from 49 to 77 hours
in B-FABP transfectants (Figure W1). In contrast, no sig-
nificant changes in doubling times were observed in U251
control transfectants compared to B-FABP–depleted U251
transfectants.
B-FABP has been postulated to be associated with radial
glial cell differentiation and process formation [6]. B-FABP
expression in malignant gliomas, therefore, may not only
Figure 2. Morphologic analysis of U87- and U251-transfected cells. (A) Phase-contrast microscopy was used to study the morphology of U87 cells stably trans-
fected with either pREP4 (R1, R2, and R3) or the pREP4/B-FABP expression construct (B1, B2, and B3). Arrowheads point to elongated processes observed in
U87 pREP4/B-FABP transfectants. (B) Phase-contrast analysis of U251 cells stably cotransfected with pSUPER (S1, S2, and S3) or pSUPER/B-FABP (B1, B2,
and B3) and pREP4. Arrowheads point to the extensive membrane ruffling observed in U251 B-FABP knockdowns.
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enhance migration properties but also be a hallmark of
increased cell differentiation and decreased cell transforma-
tion. Anchorage-independent growth is an in vitro transforma-
tion assay that correlates well with tumor formation in nude
mice [18]. U87 and U251 transfectants were plated in soft
agar, and colonies > 50 cells were counted after 4 weeks
in culture. B-FABP expression in U87 cells resulted in a sig-
nificant decrease in soft agar growth, with an average of 12
to 118 colonies/plate for U87 B-FABP transfectants, com-
pared to an average of 255 to 333 colonies/plate for control
transfectants (P < .0001) (Figure W2). A difference, albeit
of smaller magnitude, was also noted between U251 con-
trol and B-FABP–depleted transfectants, with an average
of 290 to 387 colonies/plate observed in B-FABP–depleted
Figure 3. Cell motility, migration, and invasion of U87- and U251-transfected cells. The nondirectional motility of U87 (A) and U251 (B) transfectants was measured
using 2D time-lapse video microscopy. Cells were plated in triplicate on 35-mm tissue culture dishes and imaged with phase-contrast optics using a Zeiss Axiovert
microscope with a 10 lens. The movement of 90 to 120 cells (30–40 cells/plate; three plates) was followed over a period of 2 hours, with pictures taken at
30-second intervals. Distances were measured using the Metamorph tracking function. Statistical significance was determined using unpaired t-test. Error bars
represent the standard error of the mean (SEM). (C and D) The cell migration of U87 (C) and U251 (D) transfectants was measured using the Transwell assay
(Falcon Labware). Twenty-five thousand cells were plated in triplicate and incubated for 6 hours, and the cells migrating through the porous membrane were fixed,
stained, and counted using Metamorph imaging software. Statistical significance was determined using unpaired t-test. Error bars represent standard deviation.
(E and F) Matrigel invasion of U87-transfected cells (E) and U251-transfected cells (F) using Matrigel invasion chambers. For U87 transfectants, 25,000 cells were
plated, incubated for 22 hours, and stained. For U251 transfectants, 10,000 cells were plated, incubated for 22 hours, and stained. Error bars indicate SEM.
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transfectants compared to an average of 225 to 230 colonies/
plate in control transfectants (P < .008).
Subcellular Localization of B-FABP in Malignant Glioma
Cell Lines
Cell migration involves protrusion and adhesion in front
of the cell, contraction of cell body, and detachment at
the rear [19]. These processes require actin cytoskeleton re-
modeling involving actin polymerization/depolymerization
and are regulated by small GTPases [20,21]. We used im-
munofluorescence microscopy to study the subcellular dis-
tribution of B-FABP in relation to filamentous actin. As shown
in Figure 4A, B-FABP is enriched in the nuclei of U251 con-
trol transfectants and is concentrated at the leading edge
of the cells (arrow). There is extensive staining of F-actin at
the leading edge of U251 cells, and actin stress fibers are
abundant in these cells (Figure 4B). Interestingly, there is
a significant amount of colocalization between B-FABP and
F-actin in U251 cells (Figure 4C), implying a possible as-
sociation between B-FABP and F-actin. B-FABP–depleted
U251 cells demonstrate a reduction in F-actin at the plasma
membrane, as well as a reduced number of stress fibers
(Figure 4, D and E ). There is little colocalization of B-FABP
and F-actin in these cells (Figure 4F ). B-FABP–expressing
U87 cells (U87 B-FABP3) have a staining pattern similar to
that observed in U251 control transfectants (Figure 4, G– I ).
Distribution of B-FABP in Astrocytoma Tumors
Immunohistochemical analysis of a grade II astrocytoma
indicates B-FABP expression in gemistocytic astrocytes
Figure 4. Subcellular localization of B-FABP in U87 and U251 transfectants. The subcellular location of B-FABP in U251 pSUPER3 control (A–C), U251 pSUPER/
B-FABP2 (D–F), and U87 B-FABP3 (G– I) was analyzed by immunofluorescence using (i) anti –B-FABP primary antibody followed by Alexa-488–conjugated
secondary antibody (A, D, and G) and (ii) Alexa-546 phalloidin, which stains F-actin (B, E, and H). B-FABP and F-actin signals were merged in (C), (F), and (I).
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(Figure 5). Although gemistocytes have a low prolifera-
tive index, their presence in astrocytomas is considered a
sign of poor prognosis, with gemistocyte-rich tumors rapidly
progressing to high-grade astrocytomas [22,23]. Immuno-
histochemical analysis of grade IV astrocytomas revealed
considerable variation in B-FABP expression, as previously
reported [24,25]. As we were particularly interested in the
role of B-FABP in migration and infiltration, we selected tu-
mors for analysis that contained regions of high infiltration
based on pathology reports. In Figure 6, we show a grade IV
astrocytoma specimen (patient 670) that contains the follow-
ing tissue grades: 1 = no visible tumor cells; 2 = scant tumor
cells; 3 = tumor center; and 4 = heavy tumor infiltration of the
central nervous system parenchyma. The top panel shows a
low-magnification view of tissue immunostained with anti–
B-FABP antibody and counterstained with hematoxylin. The
cortical tissue on the left is characterized by low cellular-
ity, with weak B-FABP staining that is mostly cytoplasmic
(panel 1). B-FABP staining is stronger in panel 2 but remains
primarily cytoplasmic, although some B-FABP–positive nu-
clei are observed. The tumor center (panel 3) is character-
ized by high cellularity, withf 25% of nuclei staining positive
for B-FABP. Regions of the tumor classified as heavy tumor
infiltrates (panel 4) show high cellularity, numerous blood
vessels, and abundant nuclear and cytoplasmic B-FABP
staining, especially in cells located in the vicinity of blood
vessels. The surrounding of blood vessels by B-FABP–
positive cells was commonly observed in grade IV astro-
cytomas (e.g., patient 1022; Figure 7A). Accumulation of
B-FABP–expressing cells in the subpial region of the brain
was also observed in grade IV astrocytoma (e.g., patient
1032; Figure 7B).
Discussion
Despite recent advances in the treatment of high-grade
astrocytomas, prognosis for these patients remains dismal.
Current therapies are effective at destroying cells within or
near the primary tumor mass; however, we still have no way of
identifying and targeting malignant cells that have migrated
away from the main tumor. As a result, patients with high-
grade astrocytomas consistently relapse, presenting with
secondary tumors that can be within 1 to 2 cm of—or much
more distant from—the primary tumor site. We need to find
ways of targeting malignant cells that infiltrate the brain if we
are to make an impact on the treatment of these tumors.
We have previously shown that the radial glial marker
B-FABP is expressed in astrocytoma tumors and malignant
glioma cell lines [5]. In addition to serving as a scaffold for
neuronal migration, radial glial cells can transform into
GFAP-expressing astrocytes and can also function as neu-
ronal cell progenitors [8,26]. Radial glial cells proliferate
throughout neurogenesis [27] and demonstrate neural stem
cell– like properties in embryonic and adult mice brains [28].
Two large-scale DNA microarray studies have shown an
association between B-FABP expression and astrocytomas.
In one study, B-FABP was identified as one of the top 100
genes expressed at significantly higher levels in primary
grade IV astrocytomas compared to normal brain tissues
[29]. In the second study, nuclear B-FABP expression was
shown to correlate with a worse prognosis in astrocytoma
grade IV patients below the median age [15]. A compari-
son of B-FABP levels in grade I versus grade II/III/IV astro-
cytomas and an analysis of cytoplasmic versus nuclear
B-FABP levels in grade IV astrocytomas as a function of
survival also support a link between nuclear B-FABP expres-
sion and invasion/infiltration [24,25].
Using two different assays for cell motility, one nondirec-
tional (time-lapse video microscopy) and the other directional
(Transwell chambers), we have observed striking differences
in the migration of B-FABP–expressing versus B-FABP–
negative/depleted clonal cell populations, with the former
showing much higher motility. These results are consistent
with a previous report demonstrating an increase in migra-
tion when SF767 malignant glioma cells (which express
low levels of B-FABP) are transiently transfected with a
B-FABP expression construct [15]. Although we also observe
increases in cell invasion in B-FABP–expressing clones
compared to B-FABP–negative/depleted clones, this could
be due to increased cell motility. Thus, a major consequence
of B-FABP expression in malignant glioma cells is enhance-
ment of their motility.
Radial glial cells are traditionally believed to be static, with
neuronal progeny migrating along radial glial fibers. However,
recent evidence suggests that radial glial cells are much
more than migratory guides, generating radial glial daughter
cells that migrate away from parent cells, form extended
processes, and become neurons [30]. Furthermore, the mi-
gration of radial glial cells by somal translocation has been
documented in mouse, rat, and monkey brains [8,31,32]. In
addition to longer processes, B-FABP expressing U87 cells
have a distinctive migratory behavior resembling transloca-
tion (i.e., extension of the leading process followed by
forward snapping of the cell body) as opposed to locomotion
(i.e., movement of the entire cell) [33]. In contrast, the
Figure 5. Immunohistochemical analysis of B-FABP in grade II astrocytoma.
The tissue section was immunostained with affinity-purified anti–B-FABP anti-
body and counterstained with hematoxylin. Arrows point to B-FABP–positive
gemistocytic astrocytes.
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reduction of B-FABP levels in U251 results in fan-like mem-
brane ruffling with almost no extended protrusions. Although
membrane ruffling is associated with increased cell motility, it
is the specific concentration of membrane ruffling at the ends
of lamellipodia–filopodia extensions that has been linked to
this process [34]. Fan-like structures, such as those ob-
served in B-FABP–depleted U251 cells, do not appear to
be associated with cell migration, as inhibition of these fan-
like structures does not affect cell motility [35]. The reduction
in cell migration observed on B-FABP depletion is in agree-
ment with B-FABP playing a central role in cell migration.
In vitro ligand-binding studies show that docosahexanoic
acid (DHA; 22:n  6) is the preferred ligand of B-FABP
[36,37]. DHA is the longest and most highly unsaturated fatty
acid found in membranes. Highly unsaturated long-chain fatty
acids can alter the structure and function of membranes, in-
creasing their fluidity, elasticity, and permeability, and poten-
tially affecting signal transduction and gene expression [38–
40]. Recent data support a role for DHA in the hyperfluidiza-
tion of membranes [41]. Preferential localization of B-FABP
at the leading edges of cells may result in increased DHA
content at these sites. Increased fluidity may directly promote
Figure 6. Immunohistochemical analysis of B-FABP in grade IV astrocytoma (patient 670). The tissue section was immunostained with affinity-purified anti –
B-FABP antibody and counterstained with hematoxylin. Top diagram: A low-magnification view of the entire section consisting of normal cortex and tumor tissue.
Areas labeled 1 (no visible tumor cells), 2 (scant tumor cells), 3 (tumor center), and 4 (heavy tumor infiltration of the central nervous system parenchyma) are
enlarged in the bottom panels.
B-FABP and Malignant Glioma Cell Migration Mita et al. 741
Neoplasia . Vol. 9, No. 9, 2007
cell motility or may activate cell signaling events associated
with cell motility. Future work will involve the characterization
of the effect of fatty acid ligands on the growth properties of
B-FABP–expressing malignant glioma cells.
B-FABP is primarily located in the nucleus of U251 and
B-FABP–transfected U87 cells and can be found in both
the cytoplasm and the nucleus of astrocytoma tumor cells,
in keeping with a role in the regulation of gene expression.
It has been postulated that FABP-bound fatty acids may
serve as ligands for peroxisome proliferator–activated re-
ceptors (PPARs), which then activate the transcription of
genes containing PPAR response elements [42]. PPARs
are expressed in malignant glioma cell lines, although their
relationship to B-FABP and its fatty acid ligands is not known
[43]. A link to PPARs would suggest a direct role for B-FABP
and/or its ligands in the regulation of genes involved in
cell migration.
In addition to the nucleus, B-FABP localizes to structures
associated with actin cytoskeleton remodeling and cell mi-
gration, such as stress fibers and sites of focal adhesions
(e.g., leading edges) [44]. Proteins involved in cell migration
include cadherins, integrins, actin and actin-binding pro-
teins, the Rho family of small GTPases, growth factors,
and receptors [45]. Two proteins recently implicated in ma-
lignant glioma cell migration include tyrosine kinase Pyk2,
which is believed to mediate G protein–coupled receptor
activation, and the 8-kDa polypeptide P311, which is pro-
posed to regulate malignant glioma cell motility through the
reorganization of the actin cytoskeleton [46,47]. To identify
pathways altered as a consequence of B-FABP expression,
we compared genes expressed in U87 control and B-FABP–
transfected cells. A number of differentially expressed tran-
scripts encoding proteins involved in cell migration and adhe-
sion were identified by cDNA microarray analysis, including
cadherins, laminin, tensin, and integrin b4 (our unpublished
data). Based on these preliminary results, we postulate that
the mechanism underlying B-FABP–enhanced cell migra-
tion will likely involve modulation of cell adhesion properties.
High-grade astrocytomas are highly invasive within the
brain itself; however, metastasis outside the brain is rare.
This has been attributed to the short life expectancy of the
patient and/or the blood–brain barrier. However, the blood–
brain barrier is disrupted in nearly all patients with grade IV
astrocytomas [48]. Moreover, the majority of high-grade
astrocytoma patients undergo surgery followed by radiation
treatment, which are both risk factors for metastasis [49].
Astrocytoma tumor cells have been shown to migrate along
white matter tracks, to encircle neurons and blood vessels,
and to pile up at the subpial surface of the brain [50,51]. The
B-FABP–positive cells observed in highly infiltrative regions
of grade IV astrocytomas mimic the previously reported mi-
gratory behavior of astrocytoma cells, with B-FABP–positive
cells encircling blood vessels and accumulating near the pia
mater. Of note, these features (i.e., high motility, association
with blood vessels, and white matter tracts) are also proper-
ties of neural stem cells and progenitor cells [52].
Migrating B-FABP–positive tumor cells may not be par-
ticularly tumorigenic, as suggested by the decreased prolif-
eration rate and reduced anchorage-independent growth of
B-FABP–expressing malignant glioma cells. This is consis-
tent with reports indicating that the expression of FABPs,
such as intestinal, liver, and adipocyte FABP, is reduced with
increasing malignancy, and that FABP expression is gen-
erally associated with increased differentiation [53]. The
enhanced motility associated with B-FABP–positive tumor
cells may thus represent a property associated with the cell
of origin of the tumor rather than with a consequence of
the malignant process. An intriguing observation is the pres-
ence of B-FABP in gemistocytic astrocytes in grade II astro-
cytomas. Although gemistocytes have a low proliferative
index, their presence in low-grade astrocytomas is an indi-
cation of poor prognosis, as these tumors rapidly progress
to high-grade astrocytomas [22,23]. B-FABP–expressing
gemistocytes may, therefore, represent precancerous cells
that have the potential to develop into more aggressive
cancer cells. Thus, B-FABP–positive gemistocytic astro-
cytes in low-grade astrocytomas, B-FABP–positive infiltrat-
ing tumor cells in high-grade astrocytomas, and B-FABP–
Figure 7. Immunohistochemical analysis of B-FABP in blood vessels and in
the pia surface of grade IV astrocytomas. Tissue sections from patient 1022 (A)
and patient 1032 (B) were immunostained with affinity-purified anti–B-FABP
antibody and counterstained with hematoxylin. Arrows point to blood vessels
surrounded by B-FABP–staining cells. Arrowheads point to the pia mater.
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negative proliferating cells in the tumor center may represent
transformed glial cells at different stages of the tumorigenic
process, each accompanied by progressively more muta-
tions or abnormalities. Loss of B-FABP expression may rep-
resent a relatively late tumorigenic event, allowing cells to
accumulate at one site due to decreased cell migration.
In conclusion, we have used complementary approaches
to demonstrate that B-FABP expression in malignant glioma
cells increases migratory activity. Changes in migratory
activity are accompanied by morphologic alterations: longer
processes in B-FABP–expressing U87 cells and extensive
membrane ruffling in the case of B-FABP–depleted U251
cells, suggesting a role for B-FABP in altering membrane
properties. Based on transfection experiments and immuno-
histochemical analyses of astrocytoma tumors, we propose
that the spread of astrocytoma cells within the brain is
performed through the migration of B-FABP–expressing
tumor cells that originate from radial glial cells. Manipulation
of B-FABP levels in malignant glioma cells has a dramatic
effect on their migratory and growth properties. A better
understanding of B-FABP–expressing cells may lead to
novel approaches for the treatment of both low-grade and
high-grade astrocytomas, perhaps through the manipulation
of B-FABP or its ligand DHA. B-FABP may also serve as a
useful prognostic marker for astrocytomas, particularly as
related to the prediction of tumor spread and recurrence
within the brain.
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Figure W1. Proliferation of U87- and U251-transfected cells. U87 control and B-FABP–expressing transfectants (A) and U251 control and U251-depleted
transfectants (B) were seeded at 15,000 cells/35-mm culture dish. Cells from triplicate plates were counted using a Coulter Particle and Size Analyzer (Beckman
Coulter, Fullerton, CA) at 48, 96, 144, 168, and 192 hours after plating. Growth curves were generated using the average of triplicate plates at each time point.
Doubling times were obtained using the exponential phase of the growth curves.
Figure W2. Growth of U87 and U251 transfectants in soft agar. U87 pREP4 control and pREP4/B-FABP transfectants (A) and U251 pSUPER control and
pSUPER/B-FABP transfectants (B) were plated in quadruplicate at 103 and 104 cells/dish. Colonies (> 50 cells) were counted after 4 weeks of incubation using a
Nikon Diaphot 300 light microscope with a 4 objective (Nikon, Tokyo, Japan). Error bars indicate SEM.
